For each trial, check who or what was studied, which preparation was used and what the findings support before comparing it with personal reports about individual experiences or seller listings that describe a product but don’t establish that it works.
Regulatory context
Primary evidence or regulator source
Barth syndrome patients meeting the approved Forzinity criteria; accelerated approval uses a surrogate endpoint.
Reported findings. FDA describes improved knee-extension muscle strength as the surrogate basis for accelerated Forzinity approval in eligible Barth syndrome patients; patient-function benefit requires confirmation.
Nonresponse. A post-approval randomized, double-blind, placebo-controlled trial is required to confirm whether muscle-strength changes translate into patient benefit. The announcement supplies no general response rate.
Harms. The announcement reports mild-to-moderate injection-site reactions as most common, and also serious reactions without quantifying their frequency or subtype.
Limits. Labeled preparation only; marketed variants do not inherit approval. Regulatory approval and evidence of clinical benefit are separate dimensions. The announcement does not establish effects in healthy people, other indications or research preparations.
Preparation: Forzinity (elamipretide) has accelerated FDA approval for Barth syndrome in patients weighing at least 30 kg. This does not approve other uses or research products. Route: subcutaneous Forzinity
Read original source ↗Editorial review 2026-10-15. Clinician review pending.
Human trial
Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial.
218 people with genetically confirmed primary mitochondrial myopathy; 24-week randomized comparison.
Reported findings. The study tested walking distance and fatigue; no significant benefit over placebo was established.
Nonresponse. Neither primary walking-distance nor fatigue outcome improved significantly versus placebo.
Harms. Adverse events in 107/109 versus 83/109; predominantly injection-site reactions. Discontinuations due to adverse events: 8/109 versus 2/109.
Limits. Disease-specific controlled trial does not establish energy benefits in healthy users or safety of commercial research vials.
Preparation: Controlled elamipretide preparation; research-vial equivalence unverified. Route: subcutaneous
Read original source ↗Editorial review 2026-10-09. Clinician review pending.
Human trial
A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism.
12 participants with genetically confirmed Barth syndrome; blinded crossover.
Reported findings. The controlled phase tested walking distance and symptom scores.
Nonresponse. Both primary outcomes were not significantly improved in the controlled phase.
Harms. Frequent injection-site reactions reported.
Limits. Small rare-disease crossover study; uncontrolled extension results are a separate evidence stream.
Preparation: Controlled elamipretide preparation; research-vial equivalence unverified. Route: subcutaneous
Read original source ↗Editorial review 2026-10-09. Clinician review pending.
Clinical observation
A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism.
Same TAZPOWER cohort; eight reached open-extension week 36.
Reported findings. Walking distance and symptom scores improved from baseline among extension participants.
Nonresponse. Controlled primary outcomes were null; extension has no concurrent placebo comparison.
Harms. Injection-site reactions common.
Limits. Selected extension completers; improvement from baseline is not causal proof. Later follow-up is the same cohort.
Preparation: Controlled elamipretide preparation; research-vial equivalence unverified. Route: subcutaneous
Read original source ↗Editorial review 2026-10-09. Clinician review pending.
Clinical observation
Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER.
Same TAZPOWER cohort; ten entered extension, eight reached week 168.
Reported findings. Walking, fatigue and cardiac-measure improvements reported from extension baseline.
Nonresponse. No concurrent placebo control; nonresponse beyond retained participants is not established.
Harms. Injection-site reactions were the most common adverse events.
Limits. Follow-up of the same cohort, not independent replication. Attrition and open treatment limit interpretation.
Preparation: Controlled elamipretide preparation; research-vial equivalence unverified. Route: subcutaneous
Read original source ↗Editorial review 2026-10-09. Clinician review pending.